← All trials
NCT04067414
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 14, 2018
- Primary completion
- Dec 31, 2019
- Completion date
- Dec 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Chinese Academy of Medical SciencesLead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Chinese Academy of Medical SciencesReponsible party - principal investigator
- Shanghai Cell Therapy Engineering Research InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.